3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
531
Squamous Cell Carcinoma of Head and Neck
273
Head and Neck Neoplasms
252
Lung Neoplasms
238
Uterine Cervical Neoplasms
176
Stomach Neoplasms
168
Esophageal Neoplasms
160
Nasopharyngeal Carcinoma
123
Urinary Bladder Neoplasms
116
Esophageal Squamous Cell Carcinoma
114
Neoplasms
113
Small Cell Lung Carcinoma
103
Breast Neoplasms
92
Ovarian Neoplasms
89
Neoplasm Metastasis
89
Carcinoma, Squamous Cell
76
Cholangiocarcinoma
75
Pancreatic Neoplasms
71
Biliary Tract Neoplasms
69
Mesothelioma, Malignant
57
Oropharyngeal Neoplasms
56
Carcinoma
55
Adenocarcinoma Of Esophagus
52
Recurrence
47
Parkinson Disease 4, Autosomal Dominant Lewy Body
47
Carcinoma, Ovarian Epithelial
45
Nasopharyngeal Neoplasms
41
Lymphoma
41
Adenocarcinoma of Lung
41
Gallbladder Neoplasms
38
Interventions
pembrolizumab
2
Pemetrexed
2
nilotinib
1
glutathione pegylated liposomal doxorubicin
1
ficlatuzumab
1
Zoledronic Acid
1
Trastuzumab
1
Radiosurgery
1
MRX-2843
1
Everolimus
1
Electrochemotherapy
1
Denosumab
1
Cisplatin
1
Carboplatin
1
Bleomycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplastic Processes
×
Cisplatin
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled